Ophthalmic Pipeline Oculis focuses on a differentiated ophthalmic pipeline spanning DME, DED, non-infectious uveitis, and acute optic neuritis, with topical biologic licaminlimab and other candidates, creating multiple collaboration and licensing avenues for global commercialization.

Early Commercialization The company is early in commercial activity with limited revenues, creating opportunities to monetize its portfolio through licensing, co-promotion, or exclusive distribution deals in the US and Europe, supported by upcoming clinical milestones.

Strategic Partnerships With a niche but high-need focus and an experienced management team, Oculis is well positioned to form partnerships with larger ophthalmology players to accelerate development, regulatory clearance, and market access.

Precision Medicine The PREDICT-1 genotype-based trial for licaminlimab signals a path to precision medicine in dry eye disease, offering a strong proposition for payer negotiations, biomarker-driven patient access programs, and collaborative biomarker development.

Global Footprint A transatlantic footprint with Switzerland headquarters and operations in the US and Iceland provides a solid base for a global go-to-market strategy, leveraging regional reimbursement and clinical networks to drive adoption of topical ocular therapies.